Introduction:
Cardiovascular disease is the leading cause of death worldwide. There is compelling evidence from population-based studies and clinical trials that low density lipoprotein cholesterol (LDL-C) reduction is an effective strategy to reduce coronary heart disease (CHD) events andslow CHD (1) .
Statins are powerful LDL-C lowering agents that represent the therapy of choice for primary and secondary prevention of cardiovascular events (2, 3) . Yet a significant proportion of patients remain at high risk. Some patients require larger reductions of LDL-C due to high baseline levels, such as those with familial hypercholesterolemia. Others develop adverse events and stop or discontinue current therapies (4) (5) (6) . These issues demonstrate the need for additive or replacement therapy to statins, which work by inhibiting the first enzymatic reaction of endogenous cholesterol synthesis. This review will focus on new agents targeting other molecular pathways that can lower LDL-C.
Transport and fate of body cholesterol
Cholesterol originating from either de novo synthesis or from the diet is transported in blood by apolipoprotein (apo) B and apo A containing lipoproteins ( Fig. 1) . Apo A are associated with high density lipoproteins (HDL). Lipid poor HDL are produced by the liver, the intestine or derived from chylomicrons. They take up free cholesterol from peripheral organs and macrophages and deliver it to the liver where it is excreted into the bile, an anti-atherogenic pathway known as the reverse cholesterol transport (7) . Apo B and apo A1-containing lipoprotein pathways are interconnected by a set of enzyme activities that enable lipid exchange between particles.
Cholesterol from nascent HDL is trans-esterified with phospholipid acyl chains by the enzyme lecithin:cholesterol acyltransferase (LCAT) into cholesteryl esters. Cholesteryl esters can be transferred to apo B containing lipoproteins such as very low-density lipoproteins (VLDL) or intermediary low density lipoproteins (IDL) in exchange for triglycerides (TGs) by the cholesteryl ester transfer protein (CETP) (8) . Plasma phospholipid transfer protein (PLTP) is also associated with HDL and transfers phospholipids between lipoproteins, modulating their size and composition (8) .
This review will focus on apoB-containing lipoproteins, represented by TG rich intestinal chylomicrons, and hepatic VLDL or VLDL-derived IDL and LDL (Fig. 1 ). Chylomicrons and VLDL bring fuel to peripheral organs as fatty acids and are progressively depleted of TGs by the action of lipases (9) . Thus, chylomicrons are converted into remnants and VLDL into IDL and LDL, enriched in cholesterol. LDL is removed too slowly from the circulation which allows it to exert proatherogenic properties; in particular it can be oxidized. Oxidized LDL is a source of cholesterol accumulation and foam cell formation in the artery wall.
Anti-sense oligonucleotides directed at apolipoprotein B
Disease states are often characterized by an abnormal protein or enzyme.
There are many etiologies for hypercholesterolemia, one of which is an increase in the activity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme causing increased cholesterol biosynthesis (2) . As their name implies, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), inhibit the rate limiting enzyme for cholesterol biosynthesis. However, drugs created through antisense technology act differently from traditional enzyme or proteintargeting drugs. In antisense technology, the target gene is transcribed normally from DNA to mRNA, but the mRNA is then intercepted by an antisense oligonucleotide with which it undergoes a Watson-Crick type hybridization reaction so that the mRNA can no longer be translated into a protein (10) . The antisense complex becomes a target for RNase H, an enzyme that cleaves and destroys the mRNA-antisense oligonucleotide hybrid.
Mipomersen is a polynucleotide of 20 bases that is complementary in sequence to a segment of human Apo B-100 mRNA. It specifically binds to Apo B-100 mRNA, blocking the translation of the gene product (10) (11) (12) . The inhibition of production of apo-B100 in the liver decreases levels of all apo B-containing lipoproteins, including very low-density lipoprotein (VLDL), LDL, and lipoprotein (a). Mipomersen is catabolized by endonucleases and exonucleases, which are ubiquitously expressed in all cells and tissues, and is excreted in the urine (13, 14) . It has no dependency on cytochrome P450 metabolism; consequently, there is little potential for interaction with statins, ezetimibe, bile acid binding resins, or other lipid lowering medications with which it might be used in combination.
Four phase 3 trials of mipomersen have been completed in the following patient populations: [1] homozygous FH, which occurs in 1 of 1,000,000 people (15); [2] heterozygous FH in patients with coronary artery disease (CAD) (16) ; [3] The most common adverse events leading to discontinuation with mipomersen treatment were mild-to-moderate injection site reactions and flu-like symptoms. Mipomersen has typically been shown to modestly increase hepatic fat (i.e., steatosis) in the range of 6%-12% (16, 18, 19) . 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
The hepatic LDL receptor (LDLR) plays a central role in cholesterol homeostasis (21, 22) . It is a large, complex protein with a binding domain for apo B. After apo B (as part of an apo B-containing lipoprotein) binds to LDLR, the receptor-apo B complex is internalized in a clarithrin-coated pit and enters the hepatocyte (23) . Clarithrin then dissociates from LDLR, and the apo B particle undergoes lysosomal degradation, releasing cholesterol.
The LDLR is recycled back to the surface of the hepatocyte, where it can again bind with apo B particles, enabling efficient clearance of LDL from the circulation. (Fig. 2) PCSK9, a member of the proteinase K subfamily of subtilases, is a protease involved in regulating the level of circulating LDL-C through effects on LDLR. PCSK9 regulates the surface expression of LDLR by targeting them for lysosomal degradation. PCSK9 accelerates the degradation of hepatic LDLR (24) . Thus, sustained elevation of PCSK9 levels through gain of function variants would be associated with reductions in LDLR and increases in LDL-C. Conversely, inactivation of PCSK9 or reduction in PCSK9 levels would theoretically lead to reductions in LDL-C levels.
In the Atherosclerosis Risk in Communities Study (25) , African Americans who had a loss-of-function PCSK9 mutation leading to 40-mg/dL lower LDL-C had a 90% reduction in coronary events in their middle years, from ages 40 to 55. White subjects who had another loss-of-function PCSK9 mutation, leading to 20-mg/dL lower LDL-C, had a 50% reduction in coronary events at the same ages.
Statins, bile acid sequestrants, and ezetimibe stimulate LDLR up regulation by decreasing the amount of cholesterol in the hepatocyte. This is a tightly regulated system. However, in a counter-regulatory action by the liver, statins also produce PCSK9 up-regulation (26) . Thus, the potential reduction in LDL-C provided by some LDL-C-lowering drugs is limited by this compensatory increase in PCSK9.
The strategy of PCSK9 inhibition that has progressed farthest in clinical development is neutralization of PCSK9 with a selective monoclonal antibody. By neutralizing circulating PCSK9, monoclonal antibodies prevent PCSK9-mediated catabolism of LDLR, increase LDLR density on the surface of hepatocytes, and facilitate clearance of LDL and other atherogenic lipoproteins from the circulation (27) .
Several monoclonal antibodies to PCSK9 are in clinical trial development. In the first phase 1 study of a PCSK9 monoclonal antibodies in humans, a group of healthy volunteers were administered either single-dose intravenous or subcutaneous REGN727 injections. In another phase 1 study, a group of patients with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia, who were following a modified diet, were administered multiple subcutaneous REGN727 injections on days 1, 29, and 43 (28) . In these studies the administration of REGN727 led to profound effects on LDL-C concentration. Notably, a single dose in healthy volunteers led to 50%-70% reductions in LDL-C (Fig 3) .
In a 12-week placebo-controlled study in which REGN727 was injected every 2 weeks (Q2W) or Q4W in patients with primary hypercholesterolemia (29) , there was a 31% LDL-C reduction 2 weeks after the initial 50-mg dose that decreased further to a 40% change from baseline at 12 weeks (Fig 4) . LDL-C levels after 12 weeks of 100-and 150-mg Q2W doses and 200-and 300-mg Q4W doses decreased by 64%, 72%, 43%, and 48%, respectively. These were the mean responses over time; however, the observed pattern was that upon injection of the PCSK9 monoclonal antibody there was a large decrease in LDL-C levels followed by a gradual rebound as the monoclonal antibodies were cleared from the circulation. In addition to reductions in LDL-C, TG decreased slightly (-8.4% with 300 mg), HDL-C increased (8.5% with 300 mg), and apo A1 levels increased at the greatest dose (4.2% with 300 mg). The incidence of adverse events was 45% in the group receiving placebo, 60% in the 50-mg Q2W, 65% in the 100-mg Q2W, 61% in the 150-mg Q2W, 67% in the 200-mg Q4W, and 47% in the 300-mg Q4W dosing groups (29) . There were no instances of elevated liver enzymes greater than 3 times the upper limit of normal (>3x ULN) or creatine kinase (>10x ULN) associated with administration of the PCSK9 antibody. Less than 1% of subjects reported muscle pain or weakness. Injection-site reactions occurred in the PCSK9 antibody groups but were generally mild and non-progressive. Following the discovery of the molecular cause of abetalipoprotein in the early 1990s (38, 39) , MTP became a potential therapeutic target for the treatment of both hypercholesterolemia, as well as chylomicronemia.
MTP is responsible for transferring neutral lipids (mainly triglycerides) and phospholipids onto the assembling chylomicron and VLDL particles in the intestine and the liver, respectively (40, 41) . In the absence of functional MTP, as seen in the condition of abetalipoproteinemia, apo B is not adequately lipidated in the endoplasmic reticulum and is targeted for proteosomal degradation (42) . As a result, chylomicrons and VLDL are not effectively assembled or secreted into the circulation, accounting for the absent apo B-containing lipoproteins in plasma. The discovery of the molecular basis of abetalipoproteinemia led directly to the concept that pharmacologic inhibition of MTP could be a strategy to reduce chylomicrons and LDL-C.
The only systemic MTP inhibitor that has continued to be developed beyond phase 2 clinical trials is lomitapide (formally BMS-201038 and AEGR-733). In a phase 2 double-blind placebo-controlled trial in moderately hypercholesterolemic subjects, lomitapide was dose-titrated and administered alone or in combination with ezetimibe (43) . Lomitapide alone significantly reduced LDL-C and apo B (30 and 24%, respectively at 10 mg/day); combined therapy with ezetimibe was associated with a larger LDL-C decrease (46% at 10 mg/day of both lomitapide and ezetimibe).
However, variable gastrointestinal side effects, transaminase elevations and hepatic fat increases were noted in this study.
Lomitapide was developed, in part, to treat homozygous familial hypercholesterolemia (hoFH), an autosomal dominant disorder due to impaired function of the LDLR. HoFH is characterized by markedly elevated LDL-C, often greater than 500 mg/dl, tendon xanthomas and markedly premature and progressive atherosclerosis. Because of the impaired functionality of the LDLR, hoFH patients respond inadequately to conventional drug therapies that work through LDLR upregulation (44) (45) (46) (47) .
A proof-of-concept study in six hoFH patients treated with lomitapide given as monotherapy in a dose-escalation regimen showed that doses of 0.3 and 1 mg/kg daily resulted in significant decreases in LDL-C, apo B and triglycerides, which at the higher dose were decreased by 51, 56, and 65%, respectively (48) . The reduction in LDL-C levels was accompanied by a decrease in LDL-apo B production confirming that the mechanism by which MTP inhibition decreases LDL-C levels is by reducing the hepatic secretion of apoB-containing lipoproteins.
The magnitude of LDL-C reduction with lomitapide in hoFH was confirmed in a recently published multicenter phase III study in hoFH patients, in which lomitapide was dose-titrated up to a maximum of 60 mg/day on top of standard of care, including LDL apheresis (49) . During the first 26 weeks (efficacy phase), lomitapide was gradually escalated and concomitant therapy remained unchanged. The median dose of lomitapide at the end of the efficacy phase was 40 mg/day. LDL-C, apo B and triglycerides were decreased by 50, 49 and 45%, respectively (Fig 7) , at week 26 as compared to baseline, and remained significantly reduced by 38, 43 and 31% at the end of the study, despite the changes in concomitant treatment that were allowed after week 26 (49) . This trial confirmed that the efficacy of lomitapide is additive to that of other lipid-lowering treatments, including LDL apheresis, and is stable over time. The combined efficacy on LDL-C reduction in the phase III study allowed six patients undergoing apheresis to either stop or decrease the frequency of apheresis treatments.
In addition to a reduction in other apo B-containing lipoprotein parameters, lomitapide treatment was associated with a 15% reduction in Lp(a). The mechanism of this effect is not known, but it is interesting to note that mipomersen, which also reduces LDL-C levels via a decrease in production, decreases Lp(a) as well (15) .
As expected, based on its mechanism, MTP inhibition with lomitapide is associated with the presence of gastrointestinal adverse events, including nausea, flatulence and diarrhea. Gastrointestinal adverse events were the most common reason for failure to tolerate a higher dose of lomitapide, causing three subjects to discontinue the study. Interestingly, these symptoms can be partially or completely controlled with a gradual doseescalation regimen, as well as adherence to a low-fat diet and dosing at times other than at meals (48, 49) .
Based on its mechanism, MTP inhibition is also associated with an increase in liver fat content, which has historically been the major issue with this class of drugs. In the phase 2 study of lomitapide in hoFH patients, hepatic fat was measured by nuclear magnetic resonance spectroscopy at baseline and at the end of every 4-week dose escalation: in two of the six enrolled subjects, hepatic fat at the end of treatment was minimally increased (< 10%); in two others, hepatic fat was increased to 18-24%; and in the last two subjects, hepatic fat was increased more than 30% (48).
Importantly, liver fat content and transaminase elevations were reversible with suspension of the drug (48) .
During the phase 3 study in hoFH patients treated with lomitapide, liver fat content increased from1% at baseline to 8.6% at the end of the efficacy phase (week 26) during which the dose was titrated up to a maximum of 60 mg/day. Hepatic fat content then stabilized at this level for the rest of the study (8.3% at week 78). The changes in hepatic fat content were negatively correlated with the change in LDL-C levels (49) . Approximately one-third of the patients experienced an increase in alanine aminotranferase more than three times the upper limit of normal, and this was more common in subjects with greater increases in hepatic fat.
Transaminase elevations were, however, generally transient and manageable with temporary dose reduction (49) . 
